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A b s t r A c t
Invasive aspergillosis usually occurs in immunocompromised patients, particularly 
in patients with hematological malignancies because of severe and prolonged neu-
tropenia and/or cytotoxic therapy. Treatment requires antifungal chemotherapy, with 
lipid-formulations of Amphotericin B or with azoles together with wide surgical exci-
sion of the fungal lesion. We report a case of invasive sino-orbital aspergillosis due to 
Aspergillus fumigatus in a patient with uncontrolled diabetes mellitus and small cell 
carcinoma. We support the notion that dual immunosuppression due to both diabetes 
and small cell carcinoma with liver metastases was responsible for the invasive form 
of aspergillosis in this patient.
I n t r o d u c t I o n
Invasive aspergillosis is a disease caused by filamentous fungi Aspergillus spp., 
which usually causes infection in immunocompromised patients. The most common 
pathogenic species is Aspergillus fumigatus, while Aspergillus flavus, Aspergillus terreus 
and Aspergillus niger are less commonly encountered.1,2 The majority of patients with 
invasive aspergillosis have an underlying hematological disease and/or are in a state of 
immunosuppression, such as when receiving corticosteroid and/or cytotoxic therapy, 
usually after bone marrow or solid organ transplantation, with prolonged and profound 
neutropenia (<100 cells/μl).3-6
c A s E  r E P o r t
A 72-year-old female patient presented to the hospital with ptosis of the right 
eye. Her illness had begun one month earlier with eye pain and ptosis of the right eye 
that subsequently deteriorated to complete ptosis and loss of visual acuity and color 
perception within the last one month.
Her past medical history was otherwise unremarkable, except for smoking. Labora-
tory test values were as follows: white blood cell count 5.970/mm2, hematocrit 34.9%, 
platelet count 122x103/μL, glucose 156 mg/dL, urea 50 mg/dL, creatinine 1.41 mg/dL, 
aspartate aminotransferase 18 IU/L, alanine aminotransferase 13 IU/L, alkaline phos-
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phatase 104 IU/L, creatine phosphokinase 14 IU/L, albumin 
2.4 g/dL, globulins1.83 g/dL. Computed tomography showed 
a soft tissue lesion in the right lateral sphenoid sinus extend-
ing to the right orbital apex. A cranial magnetic resonance 
imaging (MRI) examination with gadolinium revealed a local 
inhomogeneous mass involving the ethmoid and the sphenoid 
sinuses, which extended to the right orbital apex (Figure 1). 
Brain MRI did not show any pathological lesions. Laboratory 
analysis showed a glycated (glycosylated) hemoglobin A1c 
of 8.4%, thus classifying the patient as a diabetic according 
to the recent American Diabetes Association recommenda-
tions.7 The otorhinolarygologist who examined the patient 
saw a dark greyish tissue that extended through the nostrils 
and obtained a specimen for biopsy and culture. As the cul-
ture grew Aspergillus fumigatus and the histopathology of the 
specimen revealed hyphaes, liposomal amphotericin B was 
administered to the patient.
After consultation with an infectious-disease specialist, 
excision of the mass was scheduled. The surgeon removed tissue 
from the sphenoid and ethmoid sinuses and nasal turbinate and 
left an irrigating catheter in place. On histopathology, multiple 
hyphaes were seen and culture grew Aspergillus fumigatus. The 
patient received liposomal amphotericin B for two weeks after 
surgery. Because of fever that occurred in the post-operative 
period and which did not resolve despite extended-spectrum 
antimicrobial therapy and liposomal amphotericin B, the patient 
underwent brain, thoracic and abdominal computed tomog-
raphy scanning, which showed the presence of multiple liver 
lesions, suggestive of metastases. A liver biopsy was performed 
and the histopathology together with immunostaining of the 
specimen revealed small tissue carcinoma, with cytokeratin 
(CK) 7 (+), CK8/18 (+), cluster of differentiation (CD) 56 (+), 
synaptophysin (+), homeobox protein CDX-2 (-), hepatocyte 
(-), glypican-3 (-), and thyroid transcription factor-1 (TTF-1) 
(-), which is small cell carcinoma of unknown origin. Unfortu-
nately, two weeks after the operation, the patient succumbed 
to septic shock caused by Acinetobacter baumannii. 
d I s c u s s I o n
The frequency and relative importance of invasive asper-
gillosis is possibly related to increased numbers of immuno-
compromised patients, owing to improved survival from the 
acquired immunodeficiency syndrome, malignancies and more 
intensive cytotoxic therapy, more transplantation (with immu-
nosuppression) for organ dysfunction, more aggressive immu-
nosuppressive regimens for patients with autoimmune diseases 
and better therapy and prophylaxis for candida infections.8-12
Invasive aspergillosis is a devastating infection that usually 
affects patients with severe and/or prolonged neutropenia or 
neutrophil and/or macrophage dysfunction, cytotoxic chemo-
therapy, long-term corticosteroid therapy, bone marrow or 
organ transplantation, and congenital or acquired immunode-
ficiency. An aggressive diagnostic approach in patients at risk 
and prompt institution of antifungal therapy may be essential 
for patient survival.13,14
The lungs are the most common site of primary invasive 
disease, although sinus disease approaches it in frequency 
in some centers.15 Central nervous system (CNS) is the most 
common secondary site of invasive disease. Nevertheless, it is 
particularly worrisome that in about one-third of patients the 
neurological symptoms may be the first sign of invasive asper-
gillosis and that in the majority of the patients, CNS aspergil-
losis may be clinically asymptomatic until severe damage of 
the CNS has occurred. The progressive nature of this disease 
and the fact that it is relatively refractory to therapy are, in 
part, due to the organism’s rapid growth and to its tendency 
to invade blood vessels.
The major concern with Aspergillus sinonasal infections is 
its progression to the eye and/or the CNS.16 In the present case, 
the patient had invasive sinus-orbital aspergillosis and at first, 
we presumed that she was susceptible to invasive aspergillosis 
due to her indolent diabetes mellitus. Diabetes mellitus patients 
may be susceptible to fungal infections, such as aspergillosis. 
Uncontrolled and prolonged diabetes mellitus may alter the 
normal immunologic response to infections, as these patients 
have decreased phagocytic and polymorphonuclear capacity.17,18 
However, it was proved that the patient also had a small cell 
carcinoma, which had already given multiple liver metastases. 
Therefore, the patient’s susceptibility to infection with Aspergil-
FIgurE 1. Cranial MRI depicting a mass posterior to the right 
orbital cavity which invades sphenoid sinus. MRI = magnetic 
resonance imaging.
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lus fumigatus was attributed both to the underlying carcinoma 
and her uncontrolled diabetes mellitus.
Invasive aspergillosis has been described among patients 
with solid tumors, but usually after chemotherapy or after 
prolonged treatment with corticosteroids.19 It has been sug-
gested that invasive aspergillosis may be related to advanced 
stages of solid tumors as well.20,21 Our patient proved to have 
disseminated cancer, too, at the time of presentation of invasive 
aspergillosis. It is noteworthy that there have been no reports of 
co-existence of invasive aspergillosis and non-disseminated solid 
tumors, prior to chemotherapy or corticosteroid administration.
Until today, less than one hundred apparently healthy 
individuals have been described with invasive aspergillosis. 
Whether patients with invasive aspergillosis should or not be 
screened for underlying malignancies remains a matter that 
needs further investigation.
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